Latest filings (excl ownership)
8-K
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
30 Apr 24
424B5
Prospectus supplement for primary offering
26 Apr 24
8-K
Other Events
5 Apr 24
8-K
Other Events
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Mar 24
EFFECT
Notice of effectiveness
4 Mar 24
S-3
Shelf registration
23 Feb 24
S-8
Registration of securities for employees
23 Feb 24
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
15 Feb 24
10-Q
2024 Q1
Quarterly report
14 Feb 24
8-K
Other Events
14 Feb 24
ARS
2023 FY
Annual report to shareholders
26 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
8-K
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
23 Jan 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5 Jan 24
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
2 Jan 24
10-K
2023 FY
Annual report
29 Dec 23
425
Business combination disclosure
24 Oct 23
8-K
Citius Pharmaceuticals Executes Definitive Agreement to
24 Oct 23
8-K
Other Events
25 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Sep 23
8-K
Regulation FD Disclosure
11 Sep 23
8-K
Other Events
8 Sep 23
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
15 Aug 23
10-Q
2023 Q3
Quarterly report
14 Aug 23
8-K
Other Events
10 Aug 23
8-K
No clinical efficacy or safety issues raised
31 Jul 23
8-K
Regulation FD Disclosure
29 Jun 23
8-K
Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids
20 Jun 23
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update
12 May 23
10-Q
2023 Q2
Quarterly report
12 May 23
8-K
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
8 May 23
424B5
Prospectus supplement for primary offering
5 May 23
8-K
Citius Pharmaceuticals Advances Mino-LokĀ® Phase 3 Trial Achieving 85 of 92 Events to Date
24 Apr 23
8-K
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
3 Apr 23
S-8
Registration of securities for employees
10 Feb 23
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
10 Feb 23
10-Q
2023 Q1
Quarterly report
10 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
7 Feb 23
Latest ownership filings
4
Leonard L Mazur
5 Apr 24
4
MYRON Z HOLUBIAK
5 Apr 24
4
Robert Joseph Smith
18 Mar 24
3
Robert Joseph Smith
18 Mar 24
SC 13G
BlackRock Inc.
31 Jan 24
4
Carol Webb
12 Oct 23
4
Myron Czuczman
12 Oct 23
4
MYRON Z HOLUBIAK
12 Oct 23
4
Eugene Myron Holuka
12 Oct 23
4
DENNIS M MCGRATH
12 Oct 23
4
Suren G Dutia
12 Oct 23
4
Jaime Bartushak
12 Oct 23
4
Leonard L Mazur
12 Oct 23
4
DENNIS M MCGRATH
9 Feb 23
3
DENNIS M MCGRATH
9 Feb 23
4/A
Leonard L Mazur
15 Nov 22
4
William Kane
6 Oct 22
4
Suren G Dutia
6 Oct 22
4
MYRON Z HOLUBIAK
6 Oct 22
4
Leonard L Mazur
6 Oct 22
4
Jaime Bartushak
6 Oct 22
4
HOWARD SAFIR
6 Oct 22
4
Eugene Myron Holuka
6 Oct 22
4
Carol Webb
6 Oct 22
4
Myron Czuczman
6 Oct 22
SC 13G
BlackRock Inc.
8 Jul 22
SC 13D/A
Mazur Leonard L
18 Feb 22
SC 13D/A
HOLUBIAK MYRON Z
18 Feb 22
SC 13G/A
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
4
MYRON Z HOLUBIAK
13 Oct 21
4
Leonard L Mazur
13 Oct 21
4
Carol Webb
13 Oct 21
4
Jaime Bartushak
13 Oct 21
4
HOWARD SAFIR
13 Oct 21
4
Eugene Myron Holuka
13 Oct 21
4
Suren G Dutia
13 Oct 21
4
Myron Czuczman
13 Oct 21
4
William Kane
13 Oct 21
4
William Kane
26 Jul 21